Cline Scientific has been approved for listing on the Nasdaq First North Growth Market
Cline Scientific AB (“Cline” or “the Company”) has today received approval for admission to trading on the Nasdaq First North Growth Market. The first day of trading on the Nasdaq First North Growth Market falls on June 14, 2021.
Nasdaq Stockholm has today announced that Cline Scientific meets the listing requirements on Nasdaq First North Growth Market and the Company has received approval for admission to trading on Nasdaq First North Growth Market. The first day of trading on the Nasdaq First North Growth Market is June 14, 2021. Cline Scientific is previously listed on the Spotlight Stock Market, with the last day of trading being June 11, 2021.
In connection with the listing on Nasdaq First North Growth Market, Cline Scientific has appointed Redeye AB as the Company's Certified Adviser.
Cline Scientific's share will continue to be traded with ISIN code SE0006758231 and under the short name CLINE B. The company's shareholders do not need to take any measures in connection with the list change.
For more information, please contact:
Patrik Sundh, CEO
Email: patrik.sundh@clinescientific.com
Phone: +46 703-585 088
Cline Scientific AB (publ) Phone: 031-387 55 55
Argongatan 2 C Email: info@clinescientific.com
431 53 MÖLNDAL Website: www.clinescientific.com
About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. The company is working heavily with R&D through joint collaborations with pharmaceutical companies and academic researchers around the world. The focus is on projects in the cancer diagnostic and stem cell therapy fields since Clines nanotechnology here provides unmet solutions to critical challenges and functions. The unique patented surface nanotechnology is used in cell-based products and processes to drive projects within Life Science into and through the clinical phase